Clinical trials: Intestinal Obstruction
- Condition Intestinal Obstruction
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL therefore possibly…
- Trial name
- IMPROVE-Open (NCT01507220)
- Testing
- morphine sulfate, bupivacaine liposome extended-release injectable suspension
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
The purpose of this study is to assess the safety and tolerability of doripenem compared to imipenem in Ventilator-assisted pneumonia and complicated Intra-abdominal Infection.
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Abdominal Abscess
- Trial name
- NCT00515034
- Testing
- Imipenem/cilastatin, Doripenem
- Volunteers
- 146 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fibrostenotic Crohn´s Disease
A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction
This study is open to adults, between 18 and 75 years of age, who have narrowings in the small bowel (strictures) due to Crohn's disease. Strictures can lead to bowel obstruction (blockage).
- Trial name
- NCT05013385
- Testing
- Spesolimab
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Ileus
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.
- Trial name
- NCT01150760
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 7,050 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Abscess, Intra-Abdominal, Abdominal Abscess
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
- Conditions
- Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain
- Trial name
- NCT01110382
- Testing
- Doripenem, Meropenem, Amoxicillin/clavulanate potassium
- Where
- 19 sites in United States, Argentina and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Ileus, Gastro-Intestinal Disorder
A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.
- Trial name
- INTEGRITY (NCT05470387)
- Testing
- LB1148
- Where
- 23 sites in United States
- Volunteers
- 23 people
- Sponsor
- Palisade Bio
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total…
- Trial name
- IMPROVE-Lap (NCT02058290)
- Testing
- IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Intestinal Obstruction
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable…
- Trial name
- QoL in IMBO (NCT02365584)
- Testing
- lanreotide (Autogel formulation)
- Where
- 13 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Ipsen
Obstructive Defecation Syndrome, Chronic Constipation
Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
The primary purpose of this study is to determine how effective and how durable STARR (stapled transanal rectal resection) surgery is in relieving symptoms of intractable constipation associated with obstructive defecation…
- Conditions
- Obstructive Defecation Syndrome, Chronic Constipation, Rectocele, Intussusception
- Trial name
- NCT00256984
- Testing
- Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ethicon Endo-Surgery
Intestinal Obstruction
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
To assess the efficacy of Lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube (NGT) and to assess the efficacy of lanreotide Autogel 120 mg…
- Trial name
- IMIO (NCT02275338)
- Testing
- Lanreotide Autogel
- Where
- 17 sites in Belgium
- Volunteers
- 52 people
- Sponsor
- Ipsen
Bowel Obstruction
Adult Patients Undergoing Open Colectomy MA402S23B303
This study is designed to compare the standard of care against EXPAREL(R) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
- Trial name
- IMPROVE-Open (NCT01507246)
- Testing
- IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Ileus
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
This study will evaluate the safety and efficacy of two different dose regimens (12 milligrams [mg] and 24 mg) of IV MOA-728 versus placebo in shortening the time to return of bowel function in participants receiving opioid…
- Trial name
- NCT00528970
- Testing
- MOA-728
- Where
- 106 sites in United States, Australia and 9 more
- Volunteers
- 374 people
- Sponsor
- Bausch Health Americas, Inc.
Ileus, Post-Operative Adhesions
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
The purpose of this study is to establish preliminary evidence of the efficacy, safety, and tolerability of LB1148 for the treatment of post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel…
- Trial name
- PROFILE (NCT02836470)
- Testing
- LB1148
- Where
- 28 sites in United States
- Volunteers
- 112 people
- Sponsor
- Palisade Bio
Bowel Obstruction
A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly…
- Trial name
- IMPROVE-Open (NCT01507233)
- Testing
- IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Peritoneal Neoplasms, Intestinal Obstruction
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with…
- Conditions
- Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
- Trial name
- NCT00332696
- Testing
- Octreotide LAR, Octreotide (Immediate release), methylprednisolone
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Postoperative Ileus
A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo.
- Trial name
- NCT00708201
- Testing
- Alvimopan
- Where
- 20 sites in United States
- Volunteers
- 280 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Intestinal Pseudo-obstruction
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
This is a phase II, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of velusetrag once a day, compared to placebo, in subjects with CIPO.
- Trial name
- NCT05724069
- Testing
- Velusetrag 15 mg once daily for 4 weeks.
- Where
- 4 sites in Belgium, Italy and 1 more
- Volunteers
- 17 people
- Sponsor
- Alfasigma S.p.A.
Infections, Rotavirus
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247).
- Trial name
- NCT00420316
- Testing
- Rotarix (primary vaccination study)
- Where
- 15 sites in Finland
- Volunteers
- 1,613 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline